Edgestream Partners L.P. Decreases Position in Envista Holdings Co. (NYSE:NVST)

Edgestream Partners L.P. cut its position in Envista Holdings Co. (NYSE:NVST) by 24.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 114,953 shares of the company’s stock after selling 36,972 shares during the period. Edgestream Partners L.P. owned approximately 0.07% of Envista worth $2,217,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of NVST. Iron Triangle Partners LP purchased a new position in Envista in the third quarter worth about $43,262,000. Point72 Asset Management L.P. purchased a new position in Envista in the third quarter worth about $37,559,000. Polar Asset Management Partners Inc. raised its holdings in Envista by 375.6% in the third quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company’s stock worth $29,586,000 after buying an additional 1,182,450 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Envista by 26.5% in the third quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock worth $78,480,000 after acquiring an additional 830,861 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC bought a new stake in shares of Envista in the third quarter worth approximately $14,965,000.

Wall Street Analyst Weigh In

A number of analysts have recently commented on NVST shares. Wells Fargo & Company lifted their price target on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 6th. Piper Sandler lifted their price target on shares of Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Jefferies Financial Group lifted their price target on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Morgan Stanley reduced their price target on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research note on Thursday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Envista in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.38.

Envista Stock Performance

Shares of NYSE NVST opened at $18.47 on Monday. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -2.85, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista Holdings Co. has a 12-month low of $15.15 and a 12-month high of $23.00. The firm has a 50 day moving average of $20.22 and a 200 day moving average of $19.70. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, research analysts anticipate that Envista Holdings Co. will post 1 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.